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SUMMARY
In this study, methotrexate (MTX) was compared with placebo in the treatment of systemic sclerosis (scleroderma, SSc) in a 
24 week randomized double-blind trial, followed by an observational trial of 24 weeks duration. Twenty-nine scleroderma 
patients were allocated to receive weekly injections of either 15 mg MTX or placebo. Patients who responded favourably after
24 weeks continued with the same regimen for a further 24 weeks; those who showed a poor response on placebo were allocated 
to further treatment with 15 mg MTX weekly, and those who responded poorly to treatment with 15 mg MTX weekly had their 
doses increased to 25 mg. A favourable response was defined as an improvement of total skin score (TSS) by ^30% , of single 
breath diffusion capacity (DLco) by ^ 15%, or of the score on a visual analogue scale of general well-being (VAS) by ^30% , 
provided that such improvements were not accompanied by persistent digital ulcerations or worsening of DLco ^  15%. Seventeen 
patients were allocated to MTX treatment and 12 to treatment with placebo. After 24 weeks, a significantly larger number of 
patients receiving MTX (n = 8, 53%) who completed the first 24 weeks of the study had responded favourably compared to 
patients receiving placebo (n = 1, 10%, P = 0.03). Comparison of separate variables between the two treatment groups by 
intention-to-treat analysis at week 24 showed improvement in the MTX group of TSS (P = 0.06) and creatinine clearance 
(P = 0.07). At week 48, 13 patients received MTX from the start of the study and nine during 24 weeks. From these 22 patients, 
15 (68%) responded favourably and compared with the start of the study they showed significant improvement of TSS (P = 0.04), 
VAS (P = 0.02), grip strength of the right hand (P =  0.02) and ESR (P = 0.01). Although the number of patients enrolled in 
this study is small, these results suggest that in a group of patients with active systemic sclerosis, low-dose MTX seems to be 
more effective than placebo according to pre-defined response criteria.
K ey w o r d s : Systemic sclerosis, Methotrexate, Double-blind placebo-controlled treatment, Side-effects.
S y st e m ic  sclerosis (SSc) or scleroderma is a multi- 
systemic disease characterized by excessive deposition 
of collagen and other extracellular matrix components 
by fibroblasts, damage to the endothelium of small 
vessels, resulting in intimai hyperplasia and tissue 
ischaemia, and activation of the immune system. These 
phenomena may lead to progressive fibrosis of the skin, 
muscles, joints and internal organs, accounting for 
many of the clinical manifestations [1,2]. The natural 
course of the disease may vary: a few patients 
experience spontaneous remission; the majority under­
go progression of skin and internal organ involvement, 
resulting in considerable morbidity and ultimately in 
death. Several studies have given estimates o f 5 yr 
cumulative survival rates ranging from 34 to 73% [3]. 
Involvement of heart, lung or kidney, the presence of 
antitopoisomerase-I autoantibodies and diffuse skin 
involvement adversely affect outcome [4-6]. SSc is a 
rare disease, with an estimated annual incidence rate of
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20 new cases per million [7]. Its pathogenesis is unclear, 
but evidence suggests an autoimmune or vascular 
aetiology [8]. No treatment has proven convincingly to 
be effective. Several studies have reported favourable 
effects of certain drugs, but most of them consist of case 
reports, uncontrolled trials or studies with historical 
controls [9-15]. Placebo-controlled, double-blind trials 
in SSc are scarce, and have given negative or 
inconclusive results [16-22].
Methotrexate (MTX) is an antifolate drug. In low 
dosages it has shown favourable effects in the treatment 
of autoimmune diseases such as rheumatoid arthritis 
(RA) [23-27] and dermato- and polymyositis [28, 29]. 
We recently reported the results o f a 1 yr pilot study in 
SSc patients treated with low-dose MTX. In the 
majority of the patients, cutaneous symptoms im­
proved within 6 months and no further internal organ 
deterioration was detected [30]. Similar encouraging 
observations have been reported in the meantime 
[31, 32]. To obtain more data about the role of MTX 
in the treatment of SSc, we conducted a double-blind 
trial comparing MTX and placebo, focusing on the 
efficacy and toxicity of these treatments, and on the 
differences between responders and non-responders on 
MTX treatment.
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PATIENTS AND METHODS
The inclusion criteria for the trial consisted of the 
preliminary criteria for the classification of SSc of 
the American Rheumatism Association [33] and the 
requirement that disease duration from the first signs 
of skin thickening was <  3 yr. Patients with longer 
disease duration were also included if they had 
experienced a progression of skin thickening, persistent 
digital ulcerations, or a deterioration in pulmonary 
function, during the last 6 months. All patients 
voluntarily signed an informed consent form; the study 
protocol was approved by the institution’s ethical 
committee.
We applied the following exclusion criteria; age 
<16yr; the presence of another connective tissue 
disease or SSc-like illness related to exposure or 
ingestion; the presence of acute or chronic infection; 
pregnancy or childbearing potential without an 
acceptable means of contraception; the presence of 
liver disease, defined as a value exceeding twice the 
upper limit o f normal for a hepatic function test or the 
presence of a known liver disease; serum creatinine 
level >130jUmol/l or a creatinine clearance rate 
50 ml/min as estimated by the method o f Cockcroft 
and Gault [34]; total lung capacity (TLC), vital lung 
capacity (VC) or single breath diffusion capacity for
carbon monoxide (DLCo) <  50% of its predicted value; 
a leucocyte count of < 3 .5  x 109/1 or a platelet count 
<150 X I09/1; the presence of a concurrent neoplastic 
disease; the presence of insulin-dependent diabetes 
mellitus; alcohol abuse (>4oz/day); the use of an 
antifolate drug other than MTX, such as suiphonamide 
derivates, allopurinol or probenecid; and the presence 
of active peptic ulcer disease.
S tud))
multicentre
trial. The study protocol was reviewed and approved 
by institutional viewboards at each participating 
clinical centre. Patients were randomly allocated to 
treatment with either MTX (Ledertrexate, 
Nederland bv, The Netherlands) or placebo, both of 
which were administered weekly by i.m. injection. The 
two groups were balanced for disease duration (time 
between onset of skin thickening and entry to the trial) 
and extent of skin involvement, known 
factors for SSc. The weekly dose of MTX was initially 
15 mg. Potentially disease-modifying drugs, such as 
D-penicillamine and colchicine, were discontinued at 
least 3 months prior to study entry.
Since there is no consensus concerning the outcome 
measures to be used in assessing disease activity and, 
hence, response to treatment in SSc, we set up our own 
criteria by which response can be evaluated. We based 
them arbitrarily on data from previous studies and on 
our own experience. They employ the following 
variables: total skin score (TSS), which is the sum of 
scores of 0 -4  obtained manually at 26 anatomic 
locations, described by Steen et al. [9]; visual analogue
scale (VAS) of general well-being, as determined by the 
patient on a 100 mm scale on which 100 mm represents 
optimal general well-being; lung diffusion capacity as 
reflected by DLco; and presence or absence of digital 
ulcerations. Response to treatment was defined as 
favourable if TSS or VAS improved by ^  30% or if 
DLco improved by ^  15%. However, when digital 
ulcerations developed or persisted, or when DLco 
decreased by ^  15%, despite improvement of VAS or 
TSS, the response was defined as unfavourable. 
Evaluation of response criteria was performed double 
blind at weeks 24 and 48. Patients with favourable 
response after 24 weeks of treatment continued the 
same regimen for another 24 weeks. Non-responders 
on placebo after 24 weeks were started on MTX 15 mg 
weekly; non-responders on 15 mg MTX weekly 
received an increased dose of 25 mg weekly for the 
remaining 24 weeks of the trial. The clinical examiner 
and the patients were blind regarding the changes in 
treatment; the treatment code was broken only after all 
patients had completed the 48 week study. All subjects 
were out-patients at the time of enrolment and were 
admitted to hospital during the course of the study only 
in the event that severe complications occurred.
Clinical assessment 
At study entry, a detailed medical history was taken 
and the patient was given a thorough physical 
examination. Each patient was evaluated monthly 
during the trial year by the same investigator 
(FHJvdl-I). The evaluations consisted of a 
clinical examination and the determination of TSS, 
VAS, extension indices for both hands, grip strength in 
both hands and maximal oral opening. An extension 
index is the distance between the tip of the third finger 
and the distal palmar crease with the hand fully 
extended. Grip strength was measured by a sphyg-
manometer (Tonometer, von Recklinghausen,
Germany) with a range of 0-300 mmHg; the value 
recorded was the maximum of three consecutive
measurements. At study entry, and after 24 and 48
weeks of pulmonary
those r p f  pJL JLm/ j
barium swallow of the
•am
and a radiological examination
or
Laboratory assessment
•>
Haemoglobin level, white blood cell (WBC) and 
platelet counts, and hepatic and renal functions were 
evaluated weekly during the first month of treatment 
and then every 4 weeks for the remainder of the study. 
Hepatic function tests consisted of the assessment of 
alkaline phosphatase, serum aspartate aminotrans­
ferase (AST) and serum alkaline aminoti 
(ALT) levels; renal 'StS of the
assessment of serum creatinine and creatinine clearance 
rate according to the method of Cockcroft and Gault 
[34]. Other laboratory variables measured once every 4 
weeks from the beginning of therapy were erythrocyte
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sedimentation rate (ESR) according to Westergren, 
serum levels of IgA, IgM, IgG, C3, C4 and circulating 
immune complexes, and urinalysis. At study entry, 
patients were tested for antinuclear antibodies, by 
immunoblotting and counterimmunoelectrophoresis, 
and for rheumatoid factor by the latex fixation test. All 
laboratory tests, except the hepatic and renal function 
tests and those for ESR and blood cell counts, were 
performed at the University Hospital Nijmegen, to 
ensure that uniform methods were used.
Organ involvement
Pulmonary dysfunction was defined as a VC 
and TLC ^  80% or DLCo ^ 70% of predicted 
normal values, or chronic interstitial changes on 
chest roentgenograms; oesophageal dysfunction, as 
diminished motility as determined by barium swallow; 
cardiac dysfunction, as conduction disturbances on an 
EC.G or cardiomegaly on a chest X-ray; renal 
dysfunction, as serum creatinine level > 130 jumol/1 or 
a creatinine clearance rate o f <  50 ml/min as estimated 
according to the method of Cockcroft and Gault [34]. 
SSc was considered diffuse if sclerotic skin changes 
were present proximal to the elbows or knees; SSc was 
considered limited if skin changes were present distal to 
the elbows or periorally with other areas being 
unaffected.
Concurrent medication 
Concurrent treatment with corticosteroids at 
dosages not exceeding 10 mg/day, non-steroidal anti­
inflammatory drugs, analgesics, nifedipene, ketan- 
serine, cimetidine or omeprazole were permitted. No 
changes in dosages were permitted from at least 8 
weeks before study entry until the end of the trial.
was
Adverse reactions and withdrawals from the study 
At each visit, patients were routinely questioned 
about symptoms related to MTX toxicity. The trial 
medication was temporarily withheld if the WBC count
<3.0  X 10l,/l, if the platelet count was 
<150 X 107U if liver enzyme levels exceeded three 
times the upper limit of normal or if serum creatinine
exceeded 160/jmol/l, for two consecutive 
measurements. Treatment was resumed once the values 
had normalized. If the same abnormality reoccurred a 
second time, after recovery the patients received a dose 
reduced by 50%. A third occurrence resulted in the 
patient being permanently withdrawn from the study. 
Patients who failed to keep scheduled appointments at 
the clinic or whose clinical conditions deteriorated to 
such an extent as to necessitate other therapy were also 
permanently withdrawn.
Statistical analysis
*
Categorical variables were compared with Fisher’s
Wilcoxon
MTX
with those in the placebo group. Differences were 
calculated by intention-to-treat analysis (i.e. all 
patients were analysed in the group to which they were
assigned) and by same drug treatment analysis. 
Ninety-five per cent confidence intervals were
lated. For changes within the MTX group, the sign 
rank test was used. P  values of 0.05 or less were 
considered significant.
RESULTS
Patient ch or act er ist i cs
Fifty-seven patients were referred to participate in 
this trial. Twenty-eight of these patients either did not 
fulfil the inclusion criteria or were not included because 
of the exclusion criteria, thus leaving 29 patients who 
were enrolled in the study. Seventeen were allocated to 
MTX treatment and 12 to placebo treatment, 
difference in numbers resulted from the fact that by 
mistake two patients in the MTX group were initially 
recorded as belonging to the placebo group. The error 
was discovered after breaking the code at the end of the 
study. Owing to this error, the number of patients with 
diffuse and limited cutaneous involvement is also 
different, although not statistically significant, in both 
groups. Tables I and II give the initial demographic, 
clinical and laboratory data of the two groups. The
TABLE I
Patient characteristics at study entry*
Methotrexate Placebo
group group
Variable (n =  17) (11 =  12)
Age, mean ±  s.d . yr (range) 52 ±  12 (32-75) 56 ±  11 (3 9 7 2 )
Duration of cutaneous SSc,
mean ±  s.d . yr (range) 3.2 ±  6.3 (0.1 27) 3.2 ±  3.4 (0.6 12)
Sclerodematous skin
distribution
Diffuse 5 (29) 6 (50)
Limited 12 (71) 6 (50)
Male 7 (41) 2 ( 17 )t
Raynaud’s phenomenon 17 (100) 11 (92)
Duration of Raynaud’s
phenomenon mean
± s.d . yr
(range) 3.5 ±  7.0 (0.4-30) 5.6 ±  9.5 (0.9 34)
Digital ulcers/scars 12 (70) 5 (42)
Autoantibodies
ANA 15 (88) 11 (91)
Anti-TOPO 9 (53) 7 (58)
Anti-centromere 0 1 (9)
Anti-RNP 1 (6) 0
Rheumatoid factor 5 (29) 3 (25)
Prevalence o f  organ
involvement
Pulmonary 9 (53) 6 (50)
Cardiac 3 (18) 4 (33)
Renal 0 0
Oesophageal 15 (88) 10 (83)
Previous treatments
Penicillamine 6 (35) 4 (33)
Prednisone 3 (18) 4 (33)
NSAIDs 5 (29) 1 (8)
Colchicine 1 (6) 0
SSc =  systemic sclerosis; ANA — antinuclear autoantibodies;
RF =  rheumatoid factor; anti-TOPO = antitopoisomerase-I
antibodies; anti-centromere =  anticentromere antibodies; anti-
RNP =  antiribonucleoprotease antibodies.
^Values given are the number of patients and values in parentheses 
are percentages, unless otherwise indicated, 
f  P =  0.32 for differences between groups.
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Clinical and la bora lory variables: mean ±  s . d . values at study entry
Baseline
-------- • J  'V , •*V* « ■ * ■ I »
Variable
MTX group Placebo group
Total skin score 
Extension index right (mm) 
Extension index left (mm) 
Grip strength right (mmHg) 
Grip stre
Oral opening (mm)
General health (0 100 mm
(n =  17)
20.2 ± 11.0 
95.0 + 12.2
(n  =  12)
20.7 ±  11.4 
88.4 ± 20.2 
95.1 + 13.897.1 ±  15.0 
88.7 ± 70.4 116.2 ± 56.0
.5 ± 77 .1  121.8 ± 6 8 .7  
41.9 + 9.3 38.7 ± 6 .5
56.1 ± 17.354.1 ±  18.0
Lung 
Fibrosis (A?, %)
TLC ("» predicted)
VS (% predicted)
D L( 11
Cardiac ( N , %)
Renal (AO
Creatinine clearance rate 
Oesophageal (A\ ’Mi)
Creatine phosphokinase (l.)/ml) 
ESR (Westergren, mm/h)
Haemoglobin (mmol/1)
WBC ( X 1071)
5 (29) 
87.2 ±  12.7 
92.7 t  18.0 
1.42 ±  0.25
3 (18)
0
77.9 + 18.3 
15 (88) 
132.7 ±  135.4
5 (42) 
82.3 ± 16.9 
86.1 ± 20.3 
1.45 -I- 0.37
29.0 + 20.1 
8.1 +  0.9
8.4 + 2.6
y tes ( X 107D
IgA (g/l)
IgM (g/l)
IgG (g/l)
C3 (mg/1)
C4 (mg/1)
Circulating immune complexes (%)
+  0.46
349 ±  135 
3.57 ± 1 .8 1  
1.46 
16.44 
1227 
264 
3.1
4 (33)
0
75.4 ± 13.5 
10 (83)
53.5 + 37.61*■ I Ml II t
A  4* P S-m m  ♦  ¥  I . 1  
8.1 ± 0.6 
7.6 ±  1.0 
335 ±  66
2.74 ± 1.31
1.75 + 0.97
+  4.35 14.66 ±  3.95
±  308 
±  91 
±  2.4
1328 ±  300 
263 ±  74 
3.4 + 2.8
MTX — methotrexate; VAS = visual analogue scale; TLC =  total
lung capacity; VS »  vital capacity; DL™ =  diffusion capacity for 
carbon monoxide. See the text lor definitions o f organ involvement. 
f P  =  0.04 between methotexate- and placebo-treated patients.
duration of cutaneous involvement and the prevalence 
of Raynaud’s phenomenon in the two groups were 
similar. Disease duration was < 1 yr for seven patients 
(41 %) in the MTX group and four (33% ) in the placebo
MTX (29%) and six
(50%) were classified as 
having diffuse SSc. Digital ulcerations or pitting scars 
were present in 12 patients (70%) in the MTX group and 
in five (42%) in the placebo group. No autoantibodies
antitopoisomerase-1, anticentromere and 
anti-RNP antibodies and rheumatoid factor could be 
detected. CPK values were signi ficantly higher (P = 0.04) 
in the MTX group (Table II). There were no significant 
re n ces between the two groups with regard to 
internal organ involvement or previous treatment.
Response to treatment
Eight (53%) of the 15 patients in the MTX group who 
had completed the first 24 weeks had responded favour­
ably after 24 weeks, whereas nine (90%) of the patients 
receiving placebo and completing the first 24 weeks did
not res favourably (Fig. 1). is
0.03). The power lor
of responders was 0.67. 
measurements l or the mean difference in those numeric 
variables that were part of the response criterion were
<0.30 in each variable measured. The favourable
response among the patients receiving MTX was due to 
improvement in TSS in three cases, to improvement in 
VAS in four and to improvement in both in one case. 
One patient whose VAS improved ^ 30% was classified 
as a non-responder, owing to a 5*15% decrease in 
DLco. The patient who responded while undergoing 
placebo treatment had a ^30% reduction in TSS.
During the first 24 weeks of treatment, two patients 
in each treatment group had to be withdrawn from
\  H T -'•). Two both o f whom 
had been started on an increased dose of 25 mg MTX 
weekly, had to be withdrawn between weeks 24 and 48
(see further), leaving 23 patients to co
At 48, of the nine patients
trial.
transferred from placebo to MTX treatment after the 
first 24 weeks, five had responded favourably with 
^30%  improvement in TSS. Two patients who had
not responded to 15 mg MTX weekly during the first 
24 weeks responded favourably to the increased 
of 25 mg with an improvement of ^30% in VAS. 
Thus, at week 48, of the 22 patients who had completed 
the trial and had been treated with MTX for at least 
24 weeks, 15 (68%) responded favourably according to 
the pre-determined criteria.
Comparison o f  variables between groups after 24 weeks 
The differences between the initial and week 24
values of the clinical and laboratory variables ai 
shown in Table III for both groups. As there were no 
differences between the intention-to-treat analysis and 
same drug treatment analysis, only the results of the 
intention-to-treat 
following 
variables
will be
improvement of clinical 
MTX- and placebo-treated 
patients were found: (a) TSS decreased in the MTX
group and increased in the placebo group (P 0.06);
(b) VAS tended to improve in the MTX group and 
remained approximately the same in the placebo group
(P 0.19); (c) the creatinine clearance rate increased in
the MTX group and decreased in the placebo group
{P 0.07). Differences between the groups with respect
to laboratory variables consisted of a greater decrease
= 0.06)of haemoglobin level in the placebo group (P 
and WBC count in the MTX group (P = 0.003)
V I nand
MTX group (P — 0.06 and P =  0.09, respectively).
Comparison of variables after 48 weeks of methotrexate
treatment
The week 48 values were compared with the initial 
values of the patients treated with MTX throughout
the trial. Improvements were found in VAS (P
and grip of the right hand (P
Itq n p n
■ M W H 0.08)
0.04,
Table IV), which was dominant in all patients. The 
creatinine clearance rate tended to improve (P »  0.06). 
Other parameters concerning internal organs 
no change. Laboratory analysis demonstrated
in haemoglobin concentration 
0.03), WBC count {P =  0.04), thrombocyte count 
0.02), and concentrations of IgG {P =  0.0002)
(P 
(P
and C3 (P 0 .02).
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week 0 week 24 week 48
Fig . 1.— Course o f the trial.
TABLE III
Clinical and laboratory variables: differences after 24 weeks of treatment between methotrexate- and placebo-treated groups, by intention-to-tre '
analysis
MTX group In =  17) Placebo group (n — 12) P , MTX vs placebo
Total skin score - 0 . 7  ( - 3 .4 ,  2.1)* 1.2 ( - 1 .2 ,  3.5) 0.06
Extension index right (mm) - 2 .1  ( - 5 .1 ,  0.1) - 1 . 2  ( - 2 .8 ,  0.5) 0.43
Extension index left (mm) - 0 . 8  ( - 3 .4 ,  1.7) - 0 . 3  ( - 2 .6 ,  1.9) 0.44
Grip strength right (mmHg) 18.8 ( - 4 .1 ,  41.7) 12.9 ( - 1 3 .6 ,  39.4) 0.40
Grip strength left (mmHg) - 0 . 5  ( - 1 8 .4 ,  17.5) - 2 . 8  ( -1 5 .5 ,  9.8) 0.37
Oral opening (mm) - 0 . 7  ( - 1 .7 ,  0.4) — 0.2 ( —'2.1, 1.8) 0.34
General health (0-100 mm VAS) 4.5 ( - 7 .1 ,  16.0) - 1 . 0  ( - 7 .9 ,  5.9) 0.19
Organ involvement
i
Lung
Fibrosis (N , %) 5 (17) 4 (33) 0.50
TLC (% predicted) . - 1 .1  ( - 3 .4 ,  1.3) - 0 . 5  ( - 2 .2 ,  1.2) 0.43
VC (% predicted - 2 . 7  ( - 6 .7 ,  1.4) - 1 . 7  ( - 4 .9 ,  1.6) 0.37
DLco - 0 .0 3  ( - 0 .0 7 ,  0.00) -0 .0 1  ( - 0 .0 8 ,  0.08) 0.48
Cardiac (N,  %) 4 (1 5 )  • 3 (25) 1.0
Renal (N) 0 0
Creatinine clearance rate (ml/min) 4.0 ( - 0 . 6 ,  8.6) - 3 . 0  ( - 8 .7 ,  2.7) 0.07
Oesophageal {N,  %) 13 (77) 8 (67) 1.0
Creatine phosphokinase (U/ml) - 8 . 4  ( - 5 7 .9 ,  41.1) 1.7 ( - 6 .6 ,  9.9) 0.24
ESR (Westergren, mm/h) - 0 .7 1  ( - 9 . 5 ,  8.1) 2.2 ( - 6 .3 ,  10.7) 0.28
Haemoglobin (mmol/1) - 0 . 2  ( - 0 . 4 ,  0.1) - 0 . 4  ( - 0 .8 ,  - 0 .1 ) 0.06
White blood cell count ( x 109/1) - 1 . 2  ( - 2 . 1 ,  - 0 .2 ) 1.0 ( - 0 .3 ,  2.4) <0 .01
Thrombocytes ( x 109/1) - 5 3  ( - 1 1 6 ,  10) 4.5 ( - 2 7 ,  36) 0.09
IgA (g/1) - 0 .0 8  ( - 0 . 5 ,  0.3) 0.08 ( - 0 .2 1 ,  0.37) 0.15
IgM (g/1) - 0 .1 2  ( - 0 .4 1 ,  0.17) - 0 .0 5  ( - 0 .2 3 ,  0.13) 0.06
IgG (g/1) - 1 .4 0  ( - 2 .4 0 ,  -0 .4 0 ) - 0 .4 8  ( -1 .5 1 ,  0.55) 0.09
C3 (mg/1) - 1 2 2  ( - 2 4 5 ,  2) - 1 1 0  ( - 2 9 3 ,  74) 0.46
C4 (mg/1) - 0 . 7  ( - 4 4 ,  43) 13 ( - 1 9 ,  45) 0.42
Circulatory immune complexes (%) 0.07 ( - 1 .4 3 ,  1.57) 0 ( - 1 .4 7 ,  1.47) 0.44
MTX m methotrexate; VAS =  visual analogue scale; TLC — total lung capacity; VC =  vital capacity; DLco =  diffusion capacity for carbon
monoxide. See the text for definitions o f organ involvement. 
♦Values in parentheses are 95% confidence intervals.
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TABLE IV
Clinical and laboratory variables: differences with entry values after 
48 weeks of methotrexate treatment, by intention-to-treat analysis
MTX treatment (// =  17)
P , 48 week 
vs entry
Total skin scox-e - 1 .1 2  ( - 4 .2 1 ,  1.97)* 0 ">'> V /  a »kt«
Extension index right
(mm) -  1.29 ( - 5 .3 3 ,  2.74) 0.25
Extension index left
(mm) - 0 .7 7  ( - 4 .0 8 ,  2.55) 0.31
Grip strength right
(mmHg) 20.35 ( - 3 .8 9 ,  44.60) 0.04
Grip strength left
(mml-Ig) 6.00 ( -1 5 .2 5 ,  27.25) 0.28
Oral opening (mm) - 0 .1 8  ( - 1 .7 0 ,  1.35) 0.40
General health
(0-100 mm VAS) 9.88 ( - 4 .2 5 ,  24.02) 0.08
Organ involvement 
Lung
TLC (% predicted) - 1 .8 8  ( - 4 .1 8 ,  0.43) 0.95
VC (% predicted) - 3 .0 0  ( - 7 .3 5 ,  1.35) 0.42
D Leo - 0 .0 3  ( - 0 .1 1 ,  0.05) 0.29
Creatinine clearance
rate (ml/rnin) 3.18 ( - 0 .8 9 ,  7.25) 0.06
Creatine phosphokinase
(U/ml) -4 3 .7 7  ( -1 0 7 .4 2 ,  19.89) 0.08
ESR (Westergren,
mm/h) -1 .4 1  ( -1 1 .2 1 ,  8.38) 0.38
Haemoglobin (mmol/1) - 0 .2 3  ( - 0 .4 7 ,  0.01) 0.03
WBC ( x 107I) - 0 .9 7  ( - 2 .1 3 ,  0.18) 0.04
Thrombocytes ( x 109/1) -6 9 .7 7  ( -1 3 1 .6 1 ,  -7 .9 2 ) 0.02
IgA (g/1) 0.04 ( - 0 .4 1 ,  0.49) 0.43
IgM (g/1) - 0 .1 6  ( - 0 .3 9 ,  0.07) 0.08
IgG (g/1) - 1 .7 6  ( - 2 .7 0 ,  -0 .8 1 ) <  0.01
C3 (mg/1) - 1 4 6  ( - 2 8 7 ,  - 5 ) 0.02
C4 (mg/1) - 1 0 .0 6  ( -5 0 .0 2 ,  29.90) 0.30
Circulating immune
complexes (%) 1.21 ( - 0 .4 8 ,  2.91) 0.43
MTX m methotrexate; VAS =  visual analogue scale; TLC = total 
lung capacity; VC =  vital capacity; DLco =  diffusion capacity for 
carbon monoxide. See the text for definitions o f organ involvement. 
♦Values in parentheses are 95% confidence intervals.
Responders versus non-responders
Of the 15 patients who could be classified as 
responders at the end of the trial, eight achieved a 
^5 30% improvement in TSS, six a ^  30% improvement 
in VAS and one a ^30%  improvement in both. The 
initial values and the differences between the week 48 
values and the initial values of clinical and laboratory
TABLE V
Characteristics of responders (n =  15) and non-res 7) to
methotrexate therapy at study entry
Responders Non-responders
Age (y r ,  s .d .) 48.6 4- 8.2 53.5 +  12.3
Disease duration ( y r ,  s .d .) 2.4 ±  5.7 0.5 ±  0.5
Males (/?, %) 2 (15) 5 (71)*
Diffuse (n , %) 6 (40) 2 (29)
Limited (/;, %) 9 (60) 5 (71)
Antitopoisomerase-I antibodies 5 (33) 6 (86)+
Total skin score 18,6 +  6.5 18.4 -f- 9.0
For a definition o f  responders and non-rèsponders, see the text. 
*P =  0.05 and +P — 0.06 between responders and non-responders,
variables of responders compared with those of 
non-responders are shown in Table V. The difference 
between the two groups regarding disease duration was 
due to the presence of two patients with longstanding 
disease among the responders, but was not significant. 
Significantly more women than men 
favourably (P — 0.05). Antitopoisomerase-I antibodies 
seemed to be identified more frequently
non-responders (P
between
0.06). *e were
non-r
with respect to any of the other variables that were
tested at study
Diffuse and limited skin involvement, short and long 
disease duration 
There were no significant differences 
changes that occurred among patients with diffuse skin 
involvement and those that occurred among patients 
with limited skin involvement, or between the changes 
that occurred among patients with disease duration of 
> 1 yr and those that occurred among patients with 
disease duration of < 1 yr (data not shown).
Withdrawals and adverse reactions 
Withdrawals and adverse reactions are summarized 
in Table VI. One patient from the placebo group 
experienced a severe progression of cardiopulmonary 
and gastrointestinal manifestations of SSc, eventually 
accompanied by a renal crisis of which she died in week
10. Another patient had to
withdrawn in week 12, owing to renal failure due to 
scleroderma renal crisis. Two patients from the MTX 
group were also withdrawn: one in week 10 because of 
renal failure due to scleroderma renal crisis, which was 
successfully treated in the acute phase, but which left 
the patient with chronic renal failure; another because 
she suffered from persistent, severe headache after each 
injection. Two patients died between weeks 24 and 48:
one died because of
insufficiency caused by progressive pulmonary fibrosis 
the other died suddenly, presumably because 
myocardial infarction. Both patients had 
receiving an increased dose of 25 mg MTX weekly
patient who died of ec respiratory 
from a
had recovered
temporarily withholding MTX. Six patients receiving
MTX
These norm;
by elevated
in
medication had been withheld
experienced reoccurrences of 
nullities after resuming MTX. None of 
the placebo group exper 
that could be ascribed to the
This study is double-blind,
controlled study concerning MTX treatment in SSc. 
The design of this study was largely determined by the
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Patient Sex
TABLE VI
Adverse reactions, withdrawals and deaths during the study period
Side-effects
MTX
Age
Disease
duration Week 15 mg 25 mg Placebo
Temporary
withdrawal
Permanent
withdrawal Death
HH F 48 2.9 12 x liver
NH F 50 0.1 16 X liver
BM F 55 5.1 36 X liver
LG F 32 2.4 20 X liver
D A M 68 0.6 36 X liver
RA F 41 30.0 44 X liver
WE M 63 0.4 26 X pancytopenia
TA F 75 2.3 5 X headache
SC M s'y 0.8 10 X renal crisis
MO F 71 12.4 16 X renal crisis
HP F 67 0.9 36 X sudden death
WE M 63 0.4 28 X SSc-related*
EL F 68 0.8 6 X SSc-related*
*SSc-related death, death caused by SSc-related cardiopulmonary and/or renal involvement.
findings of our pilot study [30], in which skin thickening 
was reversed within 6 months of the beginning of MTX 
therapy, and no further internal organ deterioration 
occurred. It was therefore felt that, because of the 
seriousness of SSc, a potentially beneficial treatment 
could not be withheld from patients in a placebo group 
for more than 6 months. Therefore an evaluation was 
made after 24 weeks, using response criteria that were 
defined prior to the start of the study. On the basis of 
this evaluation, patients remained either on the same 
drug regimen, changed from placebo to 15 mg MTX 
per week or had the MTX dosage increased from 15 to
25 mg weekly. Although these changes in therapy were 
blinded to the clinical investigator, it appeared at the 
end of the study, when the treatment code was broken, 
that only one patient had responded to placebo. 
Because of this fact, the initial set-up of this study as 
a 48-week double-blind placebo-controlled trial could 
not be fulfilled; the placebo-controlled double-blind 
part o f this study therefore lasted 24 weeks, making 
the period between week 24 and 48 an observational 
study.
The rarity of SSc limits the number of patients 
available for trials, unless multicentre trials with 
multiobserver examinations are undertaken. However, 
multiobserver examinations are liable to diminish 
the reliability of TSS, which is the most important 
marker of disease progress. We chose one observer 
in this multicentre trial as TSS is at least as reliable 
in SSc as joint count is in rheumatoid arthritis, 
provided that it is evaluated serially by a single 
investigator [35].
The paucity of suitable disease variables makes it 
difficult to evaluate therapies for SSc. It was necessary 
to develop criteria for separating responders and 
non-responders. These employed a combination o f  
TSS, VAS, DLco and the presence or absence o f digital 
ulcers. The choice was based on findings reported in the 
literature and our own experience. Pope and Bellamy 
[36] recently reviewed the literature dealing with 
outcome measurements for treatments of scleroderma
patients in clinical trials. They too concluded that skin 
score measurements and global assessment are the best 
primary outcome measures for clinical trials; good 
secondary measures include variables of internal organ 
involvement, mortality, functional assessment, and 
physical parameters such as grip strength and extension 
index. Although the number of patients included in this 
study was small, we found that significantly more 
patients responded favourably to MTX treatment than 
placebo after 24 weeks. Analysis of results at week 48 
between the two groups could not be carried out since 
at week 24 all placebo-treated patients, except one, 
were switched to MTX treatment according to the 
study protocol. Analysis of MTX-treated patients at 
week 48, who completed the study, showed that 68% 
of the patients in the present study benefited from 
MTX treatment.
Low-dose MTX is suspected of impairing renal 
function, principally glomerular and tubular function, 
especially when it is used in combination with other 
nephrotoxic drugs [37, 38]. We found no reduction in 
renal function, as measured by creatinine clearance 
rate, as we observed in the pilot study. This may have 
been because only a few patients in the present study 
used potentially nephrotoxic drugs (non-steroidal 
anti-inflammatory drugs or cimetidine at a constant 
dose).
Only one patient had to be permanently withdrawn 
from the study because of side-effects (severe headache) 
attributable to MTX. MTX would therefore appear to 
be reasonably well tolerated and safe in low, weekly, 
i.m. dosages. The number of adverse reactions was 
relatively high, but in general minor and manageable. 
The occurrence of transient hepatic function disturb­
ances in six patients and pancytopenia in one 
emphasizes the necessity of closely monitoring hepatic 
function tests and blood cell counts.
More patients whose serum was é  • for
antitopoisomerase-I antibodies and significantly more 
patients of male gender failed to respond to MTX 
therapy. The presence of antitopoisomerase-I anti-
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bodies is also known to be associated with an 
unfavourable prognosis in SSc.
The dosage of 15 mg MTX weekly seemed to be 
sufficient for the majority of patients who responded 
favourably. A higher dose of 25 mg may be necessary 
in those cases in which it is not.
In spite of the small number of patients enrolled in 
this study, we could demonstrate that after 24 weeks a 
significantly larger number of SSc patients responded 
favourably to MTX compared to placebo treatment. 
Moreover, of all patients who received MTX for at 
least 24 weeks and completed the trial, 68% responded 
favourably to MTX therapy with reductions in skin 
thickness or improvements in general well-being and 
without further damage to internal organs after 48 
weeks. Owing to the small number of patients involved 
in this study and the limited period of follow-up, 
long-term prospective trials examining efficacy and 
toxicity and randomized trials comparing MTX with, 
for example, D-penicillamine or cyclosporin, will 
determine the position of MTX therapy in the 
treatment of scleroderma.
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